CA2506594A1 - A method for the crystallization of human serum albumin - Google Patents
A method for the crystallization of human serum albumin Download PDFInfo
- Publication number
- CA2506594A1 CA2506594A1 CA002506594A CA2506594A CA2506594A1 CA 2506594 A1 CA2506594 A1 CA 2506594A1 CA 002506594 A CA002506594 A CA 002506594A CA 2506594 A CA2506594 A CA 2506594A CA 2506594 A1 CA2506594 A1 CA 2506594A1
- Authority
- CA
- Canada
- Prior art keywords
- albumin
- crystals
- solution
- concentration
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 280
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 88
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 88
- 238000002425 crystallisation Methods 0.000 title claims abstract description 83
- 230000008025 crystallization Effects 0.000 title claims abstract description 83
- 102000009027 Albumins Human genes 0.000 claims abstract description 266
- 108010088751 Albumins Proteins 0.000 claims abstract description 266
- 239000013078 crystal Substances 0.000 claims abstract description 238
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 237
- 239000010452 phosphate Substances 0.000 claims abstract description 210
- 230000008569 process Effects 0.000 claims abstract description 162
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 111
- 238000000746 purification Methods 0.000 claims abstract description 14
- 230000001376 precipitating effect Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 93
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical group CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 92
- 102000004169 proteins and genes Human genes 0.000 claims description 86
- 235000018102 proteins Nutrition 0.000 claims description 85
- 238000000926 separation method Methods 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 68
- 239000012530 fluid Substances 0.000 claims description 53
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 50
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical group N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 36
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 35
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 35
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 32
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 31
- 230000009261 transgenic effect Effects 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000001103 potassium chloride Substances 0.000 claims description 25
- 235000011164 potassium chloride Nutrition 0.000 claims description 25
- 239000012535 impurity Substances 0.000 claims description 24
- 235000013336 milk Nutrition 0.000 claims description 24
- 239000008267 milk Substances 0.000 claims description 24
- 210000004080 milk Anatomy 0.000 claims description 24
- 238000004113 cell culture Methods 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 19
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 19
- 239000012141 concentrate Substances 0.000 claims description 16
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 11
- 208000001031 fetal erythroblastosis Diseases 0.000 claims description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000003623 Hypoalbuminemia Diseases 0.000 claims description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 206010021137 Hypovolaemia Diseases 0.000 claims description 9
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 9
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 9
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 7
- 208000034767 Hypoproteinaemia Diseases 0.000 claims description 7
- 108010011756 Milk Proteins Proteins 0.000 claims description 7
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 7
- 206010033645 Pancreatitis Diseases 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 229960002446 octanoic acid Drugs 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 102000014171 Milk Proteins Human genes 0.000 claims description 6
- 235000021239 milk protein Nutrition 0.000 claims description 6
- 208000009928 nephrosis Diseases 0.000 claims description 6
- 231100001027 nephrosis Toxicity 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 210000005253 yeast cell Anatomy 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical group N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims 26
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 8
- 206010033647 Pancreatitis acute Diseases 0.000 claims 4
- 201000003229 acute pancreatitis Diseases 0.000 claims 4
- 239000012228 culture supernatant Substances 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 230000005484 gravity Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 50
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 238000004886 process control Methods 0.000 abstract 1
- 238000010591 solubility diagram Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 78
- 235000021317 phosphate Nutrition 0.000 description 75
- 239000008118 PEG 6000 Substances 0.000 description 59
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 59
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 55
- 239000000523 sample Substances 0.000 description 54
- 239000002244 precipitate Substances 0.000 description 50
- 239000012071 phase Substances 0.000 description 33
- 239000000872 buffer Substances 0.000 description 30
- 238000000386 microscopy Methods 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 25
- 235000011152 sodium sulphate Nutrition 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 22
- 239000007788 liquid Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 239000002245 particle Substances 0.000 description 19
- 230000001788 irregular Effects 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 238000011109 contamination Methods 0.000 description 17
- 230000000813 microbial effect Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 108010076119 Caseins Proteins 0.000 description 16
- 102000011632 Caseins Human genes 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 229940044765 k-phos Drugs 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 12
- 238000005191 phase separation Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 102000004506 Blood Proteins Human genes 0.000 description 10
- 108010017384 Blood Proteins Proteins 0.000 description 10
- 102000007562 Serum Albumin Human genes 0.000 description 9
- 108010071390 Serum Albumin Proteins 0.000 description 9
- 239000005018 casein Substances 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 239000000084 colloidal system Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101710120037 Toxin CcdB Proteins 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 229940097706 buminate Drugs 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- DOBIZWYVJFIYOV-UHFFFAOYSA-N 7-hydroxynaphthalene-1,3-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(O)=CC=C21 DOBIZWYVJFIYOV-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229910003251 Na K Inorganic materials 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 235000011008 sodium phosphates Nutrition 0.000 description 4
- 230000002277 temperature effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000424725 Heide Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940021722 caseins Drugs 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000000665 Cohn process Methods 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 1
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000011548 crystallization buffer Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- SCIGVHCNNXTQDB-UHFFFAOYSA-N decyl dihydrogen phosphate Chemical compound CCCCCCCCCCOP(O)(O)=O SCIGVHCNNXTQDB-UHFFFAOYSA-N 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- MIKABIVTWXFIHG-UHFFFAOYSA-N diazanium decan-1-ol sulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCCCCO MIKABIVTWXFIHG-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 238000012835 hanging drop method Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/300,233 | 2002-11-19 | ||
| US10/300,233 US7087719B2 (en) | 2002-11-19 | 2002-11-19 | Method for the crystallization of human serum albumin |
| PCT/US2003/034205 WO2004046311A2 (en) | 2002-11-19 | 2003-10-28 | A method for the crystallization of human serum albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2506594A1 true CA2506594A1 (en) | 2004-06-03 |
Family
ID=32297870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002506594A Abandoned CA2506594A1 (en) | 2002-11-19 | 2003-10-28 | A method for the crystallization of human serum albumin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7087719B2 (https=) |
| EP (1) | EP1562991A4 (https=) |
| JP (1) | JP2006506435A (https=) |
| CN (2) | CN1732185A (https=) |
| AU (1) | AU2003285055A1 (https=) |
| CA (1) | CA2506594A1 (https=) |
| NZ (1) | NZ540149A (https=) |
| WO (1) | WO2004046311A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
| DE69933216T2 (de) * | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
| US7087719B2 (en) * | 2002-11-19 | 2006-08-08 | Gtc Biotherapeutics, Inc. | Method for the crystallization of human serum albumin |
| WO2006068548A1 (en) * | 2004-12-21 | 2006-06-29 | Telefonaktiebolaget L M Ericsson (Publ) | An arrangement and a method relating to flow of packets in communication systems |
| ES2811526T3 (es) | 2010-12-30 | 2021-03-12 | Lab Francais Du Fractionnement | Glicoles como agentes de inactivación de patógenos |
| CN102492027A (zh) * | 2011-12-09 | 2012-06-13 | 福建省农业科学院农业生物资源研究所 | 一种提取Bt杀虫蛋白晶体的方法 |
| BR112014027994A2 (pt) * | 2012-05-11 | 2017-06-27 | Novartis Ag | métodos de cristalização para purificação de anticorpos monoclonais |
| CN103012581B (zh) * | 2012-11-28 | 2015-11-25 | 李英俊 | 制备白蛋白的方法 |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| EP3016729B1 (fr) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Matrice de chromatographie d'affinité |
| CN104758924A (zh) * | 2014-01-06 | 2015-07-08 | 河南省医药科学研究院 | 包含白蛋白的药物组合物及其用途 |
| GB201409451D0 (en) | 2014-05-28 | 2014-07-09 | Ipabc Ltd | Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN105582883B (zh) * | 2015-12-25 | 2017-12-15 | 北海开元生物科技有限公司 | 一种活化硅藻土及在血液制品生产中的应用 |
| WO2019240255A1 (ja) * | 2018-06-15 | 2019-12-19 | 扶桑薬品工業株式会社 | 生殖補助医療用培地 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4833233A (en) | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| SE9101149D0 (sv) * | 1991-04-17 | 1991-04-17 | Pharmacia Lkb Biotech | Beads for down stream processing |
| US5585466A (en) | 1994-12-06 | 1996-12-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Crystals of serum albumin for use in genetic engineering and rational drug design |
| JP2004536081A (ja) | 2001-06-13 | 2004-12-02 | トーラス エイチエスエイ エルエルシー | ヒト血清アルブミンの精製 |
| US7087719B2 (en) * | 2002-11-19 | 2006-08-08 | Gtc Biotherapeutics, Inc. | Method for the crystallization of human serum albumin |
-
2002
- 2002-11-19 US US10/300,233 patent/US7087719B2/en not_active Expired - Fee Related
-
2003
- 2003-10-28 CN CNA2003801078639A patent/CN1732185A/zh active Pending
- 2003-10-28 CA CA002506594A patent/CA2506594A1/en not_active Abandoned
- 2003-10-28 AU AU2003285055A patent/AU2003285055A1/en not_active Abandoned
- 2003-10-28 JP JP2004553487A patent/JP2006506435A/ja not_active Abandoned
- 2003-10-28 NZ NZ540149A patent/NZ540149A/en unknown
- 2003-10-28 EP EP03779369A patent/EP1562991A4/en not_active Withdrawn
- 2003-10-28 CN CNA2009100046254A patent/CN101560253A/zh active Pending
- 2003-10-28 WO PCT/US2003/034205 patent/WO2004046311A2/en not_active Ceased
-
2006
- 2006-03-17 US US11/378,727 patent/US20060178309A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7087719B2 (en) | 2006-08-08 |
| WO2004046311A3 (en) | 2004-07-29 |
| WO2004046311A2 (en) | 2004-06-03 |
| CN1732185A (zh) | 2006-02-08 |
| EP1562991A2 (en) | 2005-08-17 |
| JP2006506435A (ja) | 2006-02-23 |
| AU2003285055A1 (en) | 2004-06-15 |
| CN101560253A (zh) | 2009-10-21 |
| US20060178309A1 (en) | 2006-08-10 |
| EP1562991A4 (en) | 2006-10-11 |
| NZ540149A (en) | 2008-05-30 |
| US20040097710A1 (en) | 2004-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7087719B2 (en) | Method for the crystallization of human serum albumin | |
| Koechlin | Preparation and Properties of Serum and Plasma Proteins. XXVIII. The β1-Metal-combining Protein of Human Plasma1a, b | |
| AU2007266951C1 (en) | Method for the extraction of one or several proteins present in milk | |
| JP3801196B2 (ja) | 乳からの対象化合物の単離 | |
| CA2507817C (en) | Il-21 production in prokaryotic hosts | |
| CZ286066B6 (cs) | Způsob přípravy krystalického Lys B28 Pro B29-lidského inzulínu | |
| US20050209441A1 (en) | Process for promoting proper folding of human serum albumin using a human serum albumin ligand | |
| Berridge | Preparation of the antibiotic nisin | |
| JP2006506435A5 (https=) | ||
| EP0173215A2 (en) | Method for recovering purified growth hormones from genetically engineered microorganisms | |
| RU2208637C1 (ru) | Способ получения генно-инженерного инсулина человека | |
| RU2016899C1 (ru) | Способ получения щелочной фосфатазы | |
| HK1088340A (en) | A method for the crystallization of human serum albumin | |
| Bond et al. | Expression and purification of the extracellular domain of human myelin protein zero | |
| JP3004655B2 (ja) | 結晶性ヒト顆粒球コロニー刺激因子及びその製造方法 | |
| SE445887B (sv) | Forfarande for framstellning av ett stabilt, injicerbart, zinkhaltigt insulinpreparat av tvafastyp | |
| JPH02209895A (ja) | 結晶性ヒト顆粒球コロニー刺激因子及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |